Takeda Pharmaceuticals America Inc. reported $50,000 in lobbying expenditures for Q1 2025, focusing on issues such as tax reform. This information was disclosed through a Lobbying Disclosure Act filing.
TAK Hedge Fund Activity
In the last quarter, 137 institutional investors increased their shares in TAK, while 131 reduced their positions. Notably, Mondrian Investment Partners Ltd. divested 7,737,206 shares (-100.0%) valued at approximately $102.44 million, whereas UBS Group AG increased its holdings by 1,588,617 shares (+2175.7%), valued at about $21.03 million.
TAK Analyst Ratings
Recent ratings from Wall Street analysts for $TAK include one buy rating and no sell ratings. Morgan Stanley issued an “Overweight” rating on April 2, 2025.
